Overview

A Study of Alectinib, Entrectinib, Vemurafenib Plus Cobimetinib, or Pralsetinib in Patients With Resectable Stages II-III Non-Small Cell Lung Cancer With ALK, ROS1, NTRK, BRAF V600, or RET Molecular Alterations

Status:
Recruiting

Trial end date:
2028-08-15

Target enrollment:

Participant gender:

Summary

This trial will evaluate the efficacy and safety of targeted therapies in participants with resectable Stage IIA, IIB, IIIA, and select IIIB (T3N2) resectable and untreated non-small cell lung cancer (NSCLC) tumors with selected molecular alterations.

Phase:

Phase 2

Details

Lead Sponsor:

Genentech, Inc.

Collaborator:

Blueprint Medicines Corporation

Treatments:

Entrectinib
Pralsetinib
Vemurafenib